| Applications: |
Immunodepletion/Immunocompetition |
| Note: |
STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
| Short Description: |
Protein Vestigial Blocking Peptide for STJ503517 is synthetically produced from the 200-250 sequence and is suitable for use in western blot applications. |
| Formulation: |
Liquid form at 2.5mg/ml concentration in PBS. Up to 5% DMSO can be added. Orders with >1mg can be supplied in lyophilized powder form, or in buffer of choice. |
| Storage Instruction: |
Store at-20°C for long term storage. Avoid freeze-thaw cycles. |
| Immunogen Region: |
200-250 |
| Specificity: |
This blocking peptide is recommended for use in combination with Protein Vestigial antibody, STJ503517 |
| Immunogen: |
Synthetic peptide taken within amino acid region 200-250 on D. melanogaster Vestigial protein. |
| Background | Involved in determining which thoracic imaginal disk cells will form wings and halteres, perhaps by interacting with other nuclear regulatory proteins. When in combination with scalloped (sd) , it acts as a transcriptional activation complex that regulates gene expression in the wing. Binding to sd switches the DNA target selectivity of sd. Required and sufficient for cell proliferation at the dorsal/ventral (D/V) boundary of the wing imaginal disk. Also required for cell proliferation in the wing imaginal disk, mediated via activation of E2f. By interacting with Dhfr, may control genes involved in DNA replication. |
Information sourced from Uniprot.org
12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance
